Entera Bio Ltd.
ENTX$61M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaJERUSALEM
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
May 15, 2026
9wMarket Overview
Stock performance and key metrics
ENTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
EB612 (EBP05)
Hypoparathyroidism
EBP05
Hypoparathyroidism
EnteraBio's Oral Parathyroid Hormone (1-34)
Hypoparathyroidism
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB612 (EBP05) | Phase 2 | Hypoparathyroidism | - | - |
EBP05 | Phase 2 | Hypoparathyroidism | - | - |
EnteraBio's Oral Parathyroid Hormone (1-34) | Phase 2 | Hypoparathyroidism | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply